[go: up one dir, main page]

IL161942A0 - (+)-2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol - Google Patents

(+)-2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol

Info

Publication number
IL161942A0
IL161942A0 IL16194299A IL16194299A IL161942A0 IL 161942 A0 IL161942 A0 IL 161942A0 IL 16194299 A IL16194299 A IL 16194299A IL 16194299 A IL16194299 A IL 16194299A IL 161942 A0 IL161942 A0 IL 161942A0
Authority
IL
Israel
Prior art keywords
morpholinol
chlorophenyl
trimethyl
Prior art date
Application number
IL16194299A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9801230.5A external-priority patent/GB9801230D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IL161942A0 publication Critical patent/IL161942A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL16194299A 1998-01-21 1999-01-20 (+)-2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol IL161942A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9801230.5A GB9801230D0 (en) 1998-01-21 1998-01-21 Pharmaceutically active morpholinol
US7218098P 1998-01-22 1998-01-22
PCT/US1999/001134 WO1999037305A1 (en) 1998-01-21 1999-01-20 Pharmaceutically active morpholinol

Publications (1)

Publication Number Publication Date
IL161942A0 true IL161942A0 (en) 2005-11-20

Family

ID=26312986

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13734699A IL137346A0 (en) 1998-01-21 1999-01-20 Pharmaceutically active morpholinol
IL16194299A IL161942A0 (en) 1998-01-21 1999-01-20 (+)-2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL13734699A IL137346A0 (en) 1998-01-21 1999-01-20 Pharmaceutically active morpholinol

Country Status (30)

Country Link
US (2) US6274579B1 (hu)
EP (2) EP1047428B1 (hu)
JP (1) JP2002501025A (hu)
KR (1) KR100568063B1 (hu)
CN (2) CN1203858C (hu)
AP (1) AP1229A (hu)
AT (1) ATE365042T1 (hu)
AU (1) AU755536B2 (hu)
BR (1) BR9907203A (hu)
CA (1) CA2318268A1 (hu)
CY (1) CY1106828T1 (hu)
DE (1) DE69936335T2 (hu)
DK (1) DK1047428T3 (hu)
EA (1) EA002410B1 (hu)
EE (1) EE04452B1 (hu)
ES (1) ES2288012T3 (hu)
HR (2) HRP20051024A2 (hu)
HU (1) HUP0100900A3 (hu)
ID (1) ID26334A (hu)
IL (2) IL137346A0 (hu)
IS (1) IS2494B (hu)
NO (2) NO326878B1 (hu)
NZ (3) NZ505809A (hu)
PL (1) PL193622B1 (hu)
PT (1) PT1047428E (hu)
SG (1) SG115489A1 (hu)
SK (1) SK10912000A3 (hu)
TR (1) TR200002126T2 (hu)
WO (1) WO1999037305A1 (hu)
YU (1) YU67102A (hu)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098206B2 (en) * 1998-01-21 2006-08-29 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6998400B2 (en) 1998-01-22 2006-02-14 Smithkline Beecham Corporation Pharmaceutically active morpholinol
JP2002501892A (ja) 1998-01-29 2002-01-22 セプラコア インコーポレーテッド 光学的に純粋な（−）−ビュープロピオンの薬学的使用
CA2318921A1 (en) * 1998-01-29 1999-08-05 John R. Mccullough Pharmacological uses of optically pure (+)-bupropion
US6855820B2 (en) 1999-01-20 2005-02-15 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6734213B2 (en) 1999-01-20 2004-05-11 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
US6342496B1 (en) * 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
AU7750100A (en) * 1999-10-13 2001-04-23 Glaxo Group Limited Method for the treatment of obesity
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
CA2365428C (en) * 2000-12-21 2008-10-21 Brasscorp Limited Method of producing an ultra-violet or near ultra-violet light source for non-destructive inspection or testing
US6979104B2 (en) 2001-12-31 2005-12-27 R.J. Doran & Co. LTD LED inspection lamp
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
EP2301537A1 (en) * 2002-05-17 2011-03-30 Duke University Zonisamide for the treatment of obesity
ATE413882T1 (de) * 2002-08-23 2008-11-15 Lilly Co Eli 2-(phenylthiomethyl)- morpholin-derivate zur verwendung als selektive norepinephrin- wiederaufnahme-inhibitoren
GB0219687D0 (en) * 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
KR101167579B1 (ko) 2003-04-29 2012-07-27 오렉시젠 세러퓨틱스 인크. 체중감량용 조성물
US20070093486A1 (en) * 2003-10-27 2007-04-26 Smith Kline Beecham Corporation ,Corporation Enzyme-catalyzed dynamic kinetic resolution process for preparing (+)-(2s,3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinoland salts and solvates thereof
GB0325055D0 (en) * 2003-10-27 2003-12-03 Smithkline Beecham Corp New process
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
GB0327195D0 (en) * 2003-11-21 2003-12-24 Smithkline Beecham Corp Novel use
GB0327619D0 (en) * 2003-11-27 2003-12-31 Smithkline Beecham Corp New use
US7429580B2 (en) * 2004-01-13 2008-09-30 Orexigen Therapeutics, Inc. Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
CA2565154A1 (en) * 2004-05-03 2005-11-24 Duke University Compositions for affecting weight loss
FI117283B (fi) 2005-02-04 2006-08-31 Kone Corp Hissijärjestelmä
PT2135603E (pt) 2005-11-22 2013-04-03 Orexigen Therapeutics Inc Composições e métodos para aumentar a sensibilidade à insulina
WO2007079470A2 (en) 2006-01-03 2007-07-12 Algebra, Inc. Therapeutic amine-arylsulfonamide conjugate compounds
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
TW200829235A (en) 2006-11-09 2008-07-16 Orexigen Therapeutics Inc Methods for administering weight loss medications
JP2010509367A (ja) 2006-11-09 2010-03-25 オレキシジェン・セラピューティクス・インコーポレーテッド 積層製剤
US20090075994A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched radafaxine
EP2303025A4 (en) 2008-05-30 2012-07-04 Orexigen Therapeutics Inc METHOD FOR TREATING DIGITAL FAT SWITCHES
AU2010236404B2 (en) 2009-04-15 2016-11-03 Research Triangle Institute Monoamine reuptake inhibitors
EP2523557B1 (en) 2010-01-11 2019-09-25 Nalpropion Pharmaceuticals, Inc. Methods of providing weight loss therapy in patients with major depression
WO2011146850A1 (en) 2010-05-21 2011-11-24 Research Triangle Institute Phenylmorpholines and analogues thereof
EP2571859B1 (en) * 2010-05-21 2015-07-22 Research Triangle Institute 1-phenylmorpholine derivatives as hydroxybupropion analogues for treating drug dependence
US9510405B2 (en) 2011-06-30 2016-11-29 Schneider Electric Industries Sas Dual power SMPS for a modular lighting system
CN102670617B (zh) * 2012-04-13 2013-03-20 湖南大学 布洛芬2-（2-芳基吗啉-4-基）乙酯作为制备抗抑郁药物的应用
KR20230010811A (ko) 2012-06-06 2023-01-19 오렉시젠 세러퓨틱스 인크. 과체중 및 비만의 치료 방법
CN105949142B (zh) * 2016-05-21 2018-03-27 南华大学 具有抗抑郁活性的单一手性化合物及其制备方法和应用
RU2763728C1 (ru) * 2021-06-17 2021-12-30 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) Применение 3-(2-(4-нитрофенил)-2-оксоэтилиден)морфолин-2-она в качестве средства, обладающего противомикробной активностью

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US170430A (en) * 1875-11-30 Improvement in furnaces for heating steel in tempering
GB8417170D0 (en) * 1984-07-05 1984-08-08 Wellcome Found Heterocyclic pharmaceutical compounds
GB9108629D0 (en) 1991-04-23 1991-06-12 Wellcome Found Heterocyclic pharmaceutical compounds,preparation and use
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use

Also Published As

Publication number Publication date
HUP0100900A3 (en) 2002-08-28
EE04452B1 (et) 2005-04-15
AU755536B2 (en) 2002-12-12
US20020019396A1 (en) 2002-02-14
HRP20000494B1 (en) 2009-02-28
NO20083529L (no) 2000-09-19
HRP20051024A2 (hr) 2006-04-30
WO1999037305A1 (en) 1999-07-29
NZ505809A (en) 2002-09-27
NZ529316A (en) 2004-05-28
YU67102A (sh) 2004-12-31
AU2328099A (en) 1999-08-09
PT1047428E (pt) 2007-09-07
PL193622B1 (pl) 2007-02-28
DE69936335T2 (de) 2008-02-28
EP1047428B1 (en) 2007-06-20
CN1528753A (zh) 2004-09-15
KR20010034285A (ko) 2001-04-25
JP2002501025A (ja) 2002-01-15
SK10912000A3 (sk) 2001-04-09
IL137346A0 (en) 2001-07-24
SG115489A1 (en) 2005-10-28
EP1829544A1 (en) 2007-09-05
NO20003721L (no) 2000-09-19
US6274579B1 (en) 2001-08-14
CN1255389C (zh) 2006-05-10
EP1047428A4 (en) 2001-12-19
AP1229A (en) 2003-12-04
DK1047428T3 (da) 2007-10-08
BR9907203A (pt) 2000-10-17
CY1106828T1 (el) 2012-05-23
CN1203858C (zh) 2005-06-01
NO326878B1 (no) 2009-03-09
EP1047428A1 (en) 2000-11-02
EE200000438A (et) 2001-12-17
US6391875B2 (en) 2002-05-21
KR100568063B1 (ko) 2006-04-07
CN1294513A (zh) 2001-05-09
AP2000001869A0 (en) 2000-09-30
ID26334A (id) 2000-12-14
NO20003721D0 (no) 2000-07-20
PL342012A1 (en) 2001-05-07
DE69936335D1 (de) 2007-08-02
ES2288012T3 (es) 2007-12-16
ATE365042T1 (de) 2007-07-15
EA200000691A1 (ru) 2001-04-23
EA002410B1 (ru) 2002-04-25
NZ520349A (en) 2004-02-27
TR200002126T2 (tr) 2000-12-21
HUP0100900A2 (hu) 2002-05-29
CA2318268A1 (en) 1999-07-29
IS2494B (is) 2009-02-15
IS5568A (is) 2000-07-20
HRP20000494A2 (en) 2000-12-31

Similar Documents

Publication Publication Date Title
IL161942A0 (en) (+)-2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol
DE69941083D1 (en) 12,13-cyclopropan-epothilonderivate
IL143859A0 (en) 1,2-annelated quinoline derivatives
GB9929000D0 (en) Reamer shoe
HUP0102483A3 (en) Pharmaceutical compositions containing androst-5-ene-3betha,17betha-diol
GB9814325D0 (en) Headwear
ZA200005510B (en) Pharmaceutical composition.
ZA200005369B (en) Calcilytic compounds.
GB9817235D0 (en) Compound,composition and use
PL352285A1 (en) Phenoxy fluoropyrimidines
GB9903447D0 (en) Compound, composition and use
ZA992899B (en) Novel compound.
AU2656799A (en) Metal-thiols as imminomodulating agents
GB0100361D0 (en) Compound, composition and use
ZA200006118B (en) Novel composition.
AU2964899A (en) 2,4-dioxo-5-arylidenimino-1,3-pyrimidines
ZA991761B (en) New agent.
ZA993225B (en) Cooling reservoir.
ZA200000192B (en) Novel composition.
AU3196000A (en) 3,3'-diketotrehalose
ZA99985B (en) New compound.
IL158978A (en) Salts and solvates of the compound (+)-(2s,3s)-2-(3-chlorophenyl) -3,5,5- trimethyl-2-morpholinol
ZA99925B (en) Composition.
ZA997202B (en) Pharmaceutical composition.
GB9826627D0 (en) Alloy